{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:40:04Z","timestamp":1790991604061,"version":"4.1.0"},"reference-count":59,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2022,12,19]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>Toxic neuropathies result from exogenous substances damaging the peripheral nerves. There are numerous causes, including prescribed and recreational drugs, heavy metals, industrial agents and biological toxins. Timely recognition of these neuropathies gives better outcomes, as they usually improve or stabilise once the toxin is removed. Most toxic neuropathies are axonal, length-dependent and sensory predominant, although some have significant motor involvement or can present acutely or subacutely. Here, we outline our clinical approach and discuss the major causes of toxic neuropathy, while emphasising the clinical and neurophysiological features and the neuropathy phenotype. We also include an update on newer medications that can cause neuropathy, including immune checkpoint inhibitors and BRAF\/MEK inhibitors.<\/jats:p>","DOI":"10.1136\/pn-2022-003444","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T13:21:11Z","timestamp":1674652871000},"page":"120-130","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Toxic neuropathies: a practical approach"],"prefix":"10.1136","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-8611","authenticated-orcid":false,"given":"Duncan","family":"Smyth","sequence":"first","affiliation":[{"name":"MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kramarz","sequence":"additional","affiliation":[{"name":"MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling S","family":"Carr","sequence":"additional","affiliation":[{"name":"MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-2896","authenticated-orcid":false,"given":"Alexander M","family":"Rossor","sequence":"additional","affiliation":[{"name":"MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-6027","authenticated-orcid":false,"given":"Michael P","family":"Lunn","sequence":"additional","affiliation":[{"name":"MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2025090410430790000_23.2.120.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951"},{"key":"2025090410430790000_23.2.120.2","doi-asserted-by":"crossref","unstructured":"Hertz DL , Tofthagen C , Faithfull S . Predisposing Factors for the Development of Chemotherapy-Induced Peripheral Neuropathy (CIPN). In: Lustberg M , Loprinzi C , eds. Diagnosis, management and emerging strategies for chemotherapy-induced neuropathy: a MASCC book. Cham: Springer International Publishing, 2021: 19\u201351.","DOI":"10.1007\/978-3-030-78663-2_2"},{"key":"2025090410430790000_23.2.120.3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7286"},{"key":"2025090410430790000_23.2.120.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.077"},{"key":"2025090410430790000_23.2.120.5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21204"},{"key":"2025090410430790000_23.2.120.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.03.024"},{"key":"2025090410430790000_23.2.120.7","first-page":"3633","article-title":"Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review","volume":"24","author":"Fernandes","year":"2016","journal-title":"Support Care Cancer"},{"key":"2025090410430790000_23.2.120.8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1356::AID-CNCR20>3.0.CO;2-#"},{"key":"2025090410430790000_23.2.120.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.626687","article-title":"Neuroinflammatory process involved in different preclinical models of chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fumagalli","year":"2020","journal-title":"Front Immunol"},{"key":"2025090410430790000_23.2.120.10","doi-asserted-by":"crossref","first-page":"A44.2","DOI":"10.1136\/jnnp-2022-ABN.141","article-title":"105 Broadening the clinical spectrum of bortezimib induced peripheral neuropathy: 4 illustrative cases","volume":"93","author":"Grundy","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090410430790000_23.2.120.11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"J Neurooncol"},{"key":"2025090410430790000_23.2.120.12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795"},{"key":"2025090410430790000_23.2.120.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw558"},{"key":"2025090410430790000_23.2.120.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001"},{"key":"2025090410430790000_23.2.120.15","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1111\/bcp.15513","article-title":"Peripheral neuropathies after BRAF and\/or MEK inhibitor treatment: a pharmacovigilance study","volume":"88","author":"Picca","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025090410430790000_23.2.120.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813"},{"key":"2025090410430790000_23.2.120.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198308253090801"},{"key":"2025090410430790000_23.2.120.18","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/advances\/nmab033","article-title":"Vitamin B-6-induced neuropathy: exploring the mechanisms of pyridoxine toxicity","volume":"12","author":"Hadtstein","year":"2021","journal-title":"Adv Nutr"},{"key":"2025090410430790000_23.2.120.19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jns.12480","article-title":"Vitamin B6 levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy","volume":"27","author":"Stewart","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"2025090410430790000_23.2.120.20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jctube.2015.11.002","article-title":"Peripheral neuropathy in persons with tuberculosis","volume":"2","author":"Mafukidze","year":"2016","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2025090410430790000_23.2.120.21","article-title":"A case report: ethambutol causes a rare adverse effect of peripheral neuropathy","volume":"14","author":"Rana","year":"2022","journal-title":"Cureus"},{"key":"2025090410430790000_23.2.120.22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr233"},{"key":"2025090410430790000_23.2.120.23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10072-017-2993-7","article-title":"Phenytoin: neuroprotection or neurotoxicity?","volume":"38","author":"Keppel Hesselink","year":"2017","journal-title":"Neurol Sci"},{"key":"2025090410430790000_23.2.120.24","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200010000-00014"},{"key":"2025090410430790000_23.2.120.25","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025090410430790000_23.2.120.26","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Z429"},{"key":"2025090410430790000_23.2.120.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.016"},{"key":"2025090410430790000_23.2.120.28","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy","volume":"316","author":"Kuncl","year":"1987","journal-title":"N Engl J Med"},{"key":"2025090410430790000_23.2.120.29","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90444-X"},{"key":"2025090410430790000_23.2.120.30","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1984.01650390078016"},{"key":"2025090410430790000_23.2.120.31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1445-5994.1981.tb03521.x","article-title":"Nitrofurantoin neuropathy","volume":"11","author":"Yiannikas","year":"1981","journal-title":"Aust N Z J Med"},{"key":"2025090410430790000_23.2.120.32","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.31.6.730","article-title":"Disulfiram neuropathy","volume":"31","author":"Mokri","year":"1981","journal-title":"Neurology"},{"key":"2025090410430790000_23.2.120.33","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(84)90200-4"},{"key":"2025090410430790000_23.2.120.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01109-0"},{"key":"2025090410430790000_23.2.120.35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijantimicag.2017.08.033","article-title":"Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature","volume":"51","author":"Goolsby","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2025090410430790000_23.2.120.36","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20924"},{"key":"2025090410430790000_23.2.120.37","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12324"},{"key":"2025090410430790000_23.2.120.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2007.10.014"},{"key":"2025090410430790000_23.2.120.39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2169\/internalmedicine.51.6320","article-title":"Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon \u03b1-2b: a neuropathology case report","volume":"51","author":"Shiga","year":"2012","journal-title":"Intern Med"},{"key":"2025090410430790000_23.2.120.40","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s00415-018-9123-1","article-title":"Alcohol-related peripheral neuropathy: a systematic review and meta-analysis","volume":"266","author":"Julian","year":"2019","journal-title":"J Neurol"},{"key":"2025090410430790000_23.2.120.41","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410020203"},{"key":"2025090410430790000_23.2.120.42","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10550"},{"key":"2025090410430790000_23.2.120.43","unstructured":"UK Parliament . Nitrous oxide: no laughing matter? Available: https:\/\/commonslibrary.parliament.uk\/nitrous-oxide-no-laughing-matter\/ [Accessed 05 Sep 2022]."},{"key":"2025090410430790000_23.2.120.44","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2014-001071"},{"key":"2025090410430790000_23.2.120.45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/01616412.2019.1588490","article-title":"Characteristics of patients with vitamin B12-responsive neuropathy: a case series with systematic repeated electrophysiological assessment","volume":"41","author":"Franques","year":"2019","journal-title":"Neurol Res"},{"key":"2025090410430790000_23.2.120.46","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1007\/s00415-021-10858-2","article-title":"Nitrous oxide-induced predominantly motor neuropathies: a follow-up study","volume":"269","author":"Berling","year":"2022","journal-title":"J Neurol"},{"key":"2025090410430790000_23.2.120.47","unstructured":"Health and Safety Executive . Exposure to lead in Great Britain, 2021, 2022."},{"key":"2025090410430790000_23.2.120.48","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20510"},{"key":"2025090410430790000_23.2.120.49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/B978-0-444-62627-1.00015-9","article-title":"Clinical description of toxic neuropathies","volume":"131","author":"Little","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"2025090410430790000_23.2.120.50","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.933.391"},{"key":"2025090410430790000_23.2.120.51","doi-asserted-by":"publisher","DOI":"10.1136\/oem.57.1.19"},{"key":"2025090410430790000_23.2.120.52","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.129049"},{"key":"2025090410430790000_23.2.120.53","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(91)90022-Y"},{"key":"2025090410430790000_23.2.120.54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1212\/WNL.47.1.18","article-title":"Axonal channelopathies: an evolving concept in the pathogenesis of peripheral nerve disorders","volume":"47","author":"Gutmann","year":"1996","journal-title":"Neurology"},{"key":"2025090410430790000_23.2.120.55","doi-asserted-by":"crossref","first-page":"13031","DOI":"10.1007\/s11356-020-12287-6","article-title":"Acrylamide-induced peripheral neuropathy: manifestations, mechanisms, and potential treatment modalities","volume":"28","author":"Bin-Jumah","year":"2021","journal-title":"Environ Sci Pollut Res Int"},{"key":"2025090410430790000_23.2.120.56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0975-7406.164293","article-title":"Laboratory approach for diagnosis of toluene-based inhalant abuse in a clinical setting","volume":"8","author":"Jain","year":"2016","journal-title":"J Pharm Bioallied Sci"},{"key":"2025090410430790000_23.2.120.57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clineuro.2010.08.015","article-title":"Organophosphate induced delayed polyneuropathy in man: an overview","volume":"113","author":"Jokanovi\u0107","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"key":"2025090410430790000_23.2.120.58","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)61587-1","article-title":"Mees' lines","volume":"372","author":"Chauhan","year":"2008","journal-title":"Lancet"},{"key":"2025090410430790000_23.2.120.59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10408363.2021.1885339","article-title":"Vitamin B\n                  12\n                status in health and disease: a critical review. Diagnosis of deficiency and insufficiency - clinical and laboratory pitfalls","volume":"58","author":"Sobczy\u0144ska-Malefora","year":"2021","journal-title":"Crit Rev Clin Lab Sci"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2022-003444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:43:23Z","timestamp":1757007803000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2022-003444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/pn-2022-003444"],"URL":"https:\/\/doi.org\/10.1136\/pn-2022-003444","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}